Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] ALL is engaged in contract manufacturing of pharma and cosmetic products for domestic and export markets. While it marked growth in its top lines, its bottom lines boosted fromFY24 onwards and raised eyebrows. Based on its financial data so far, the issue appears fully priced. Well-informed investors may park funds for medium to long term. Read detail review...
Astonea Labs Ltd peer comparison with similar listed entities. (As on March 28, 2024)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Astonea Labs Ltd | 5.01 | 5.01 | 15.75 | 31.83 | 9.00 | Restated | |
Beta Drugs Limited | 37.90 | 37.90 | 163.43 | 49.00 | 23.19 | 11.39 | Consolidated |
Source:
Astonea Labs IPO Reviews, analysis and views by popular members. Read Astonea Labs Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Note: